Weekly penMounjaro
Tirzepatide · Once a week, same day
SURMOUNT-1, 72 weeks
- One injection a week, on a day you choose
- Works on two appetite hormones, not one
- The largest average weight loss of the four
From £195 a month
Read about MounjaroOnline weight loss treatments
Four licensed options, two pens and two tablets. One clinician decision, made with your history rather than a headline.
From £120 a month

The options
Weekly penTirzepatide · Once a week, same day
From £195 a month
Read about Mounjaro
Weekly penSemaglutide · Once a week, same day
From £139 a month
Read about Wegovy
Daily tabletOral semaglutide · Once a day, before food
From £125 a month
Read about Wegovy tablets
Daily tabletOrforglipron · Once a day, any time
From £120 a month
Read about FoundayoSide by side
Swipe the table sideways
Trial figures come from separate studies and are not head-to-head comparisons. Averages, not promises.
Which one suits you
“I want the biggest result”
You want the largest average result and are happy with a weekly injection.
Mounjaro
“I do not want needles”
You want the results of semaglutide without an injection.
Wegovy tablets
“I want the simplest daily routine”
You want the simplest possible daily routine and the lowest starting price.
Foundayo
Choose a treatment to project
Your projection
Put in your details to see a personalised trajectory over 72 weeks, based on Mounjaro trial outcomes.
Included either way
Clinician review
Before anything is issued
UK pharmacy
GPhC registered, MHRA regulated
Free delivery
Next weekday, tracked
WhatsApp support
Seven days a week
Progress check-ins
As your dose steps up
Cancel any time
No lock-in, no consultation fee
Questions
In head-to-head terms, tirzepatide (Mounjaro) has produced the largest average weight loss of the licensed options in the UK: around 20.9% of body weight over 72 weeks in SURMOUNT-1, compared with about 14.9% for semaglutide 2.4mg (Wegovy) over 68 weeks in STEP 1. Trials are not directly comparable, and the best treatment for an individual is the one they tolerate and can keep taking, which is why a prescriber weighs medical history and side-effect risk rather than the headline figure alone.
Authored by · 18 August 2026
Ali Salih — MPharm
Prescribing pharmacist
GPhC 2212755
Reviewed by · 18 August 2026
Dr A Ameer
Clinical pharmacist, medical review
UK-registered healthcare professional
Prescription, clinician review and pharmacy delivery included. You only pay if our clinicians approve your treatment.
No charge unless our clinicians approve your treatment
